InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
6
T+90 hit rate
40%
T+90 mean return
-8.7%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Butler John P., Chairman & CEO. Officer active across 2 companies, notably Zynerba Pharmaceuticals, Inc.. In total, 17 disclosures have been published. Split: 0 buy · 6 sells. Total volume traded: €312k. History available since 3 August 2021. The latest transaction was filed on 3 March 2025 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations17 total
46,409 shares@ US$1.8326.1% of flowCommon StockSEC:0001562180-25-001998:0
701,000 shares0Common StockSEC:0001562180-25-000917:0
46,570 shares@ US$1.5821.8% of flowCommon StockSEC:0001562180-24-002021:0
37,733 shares@ US$1.5216.9% of flowCommon StockSEC:0001562180-24-001992:0
603,500 shares0Common StockSEC:0001562180-24-000971:0
32,941 sharesCommon StockSEC:0001140361-23-047727:0
47,824 shares0Common StockSEC:0001062993-23-013664:0
38,259 shares@ US$0.877510.2% of flowCommon StockSEC:0001562180-23-002201:0
38,632 shares@ US$0.81329.5% of flowCommon StockSEC:0001562180-23-002041:0
293,125 shares0Common StockSEC:0001562180-23-000832:0
23,109 shares0Common StockSEC:0001062993-22-015037:0
25,053 shares@ US$2.15480.017% mcap100.0% of flowCommon StockSEC:0001562180-22-002166:0
1,248 sharesCommon StockSEC:0001562180-22-001654:0
1,248 sharesCommon StockSEC:0001562180-22-001654
5,000 shares0Common StockSEC:0001192482-21-000646:0
5,000 shares0Common StockSEC:0001192482-21-000646
25,000 sharesCommon StockSEC:0001209191-16-092030:0
17 of 17 declarations
About Butler John P.
John P. Butler is the CEO and President of Zynerba Pharmaceuticals, Inc. and Akebia Therapeutics, Inc. He leads these companies with an innovation-driven approach in the biopharmaceutical field. John is committed to developing treatments that address unmet patient needs.
